BW
CD142 (Phospho-S290) polyclonal Antibody | BS64521
- SKU:
- BW-BS64521
- Availability:
- Usually ships in 5 working days
Description
CD142 (Phospho-S290) polyclonal Antibody | BS64521 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human,Rat
Application: WB IHC
Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200
Background: Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (Prothrombin and Factors X, IX, V and VIII), which are involved in a blood coagulation cascade leading to the formation of insoluble Fibrin clots and the promotion of platelet aggregation. Coagulation Factor V (Factor V, FV, proaccelerin, labile factor) is a 2196 amino acid, single chain glycoprotein that is cleaved by Thrombin to yield an active, Ca2+-dependent dimer that is essential to the blood coagulation cascade. Together with catalytic Factor Xa and Ca2+ on the surface of platelets or endothelial cells, Factor Va coordinates into a Prothrombinase complex, which mediates proteolysis of Prothrombin into active Thrombin. Tissue factor (TF), also designated coagulation Factor III is a cell surface glycoprotein that enables cells to initiate blood coagulation cascades. It functions as a high-affinity receptor for coagulation Factor VII.
Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity: CD142 (Phospho-S290) polyclonal Antibody detects endogenous levels of CD142 protein only when phosphorylated at Ser290.
Molecular Weight: ~ 45 kDa
Note: For research use only, not for use in diagnostic procedure.
Alternative Names: Tissue factor; TF; Coagulation factor III; Thromboplastin; CD142; F3
Immunogen: Synthetic phosphopeptide derived from human CD142 around the phosphorylation site of Serine 290.
Conjugate: Unconjugated
Modification: Phosphorylation
Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .
Pathway: